Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Routine tests of haemostasis and low-oestrogen oral contraceptives : what to expect? (CROSBI ID 208972)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Zadro, Renata ; Oslaković, Sandra Routine tests of haemostasis and low-oestrogen oral contraceptives : what to expect? // Clinical laboratory (Heidelberg. 1996), 60 (2014), 5; 827-832. doi: 10.7754/Clin.Lab.2013.130533

Podaci o odgovornosti

Zadro, Renata ; Oslaković, Sandra

engleski

Routine tests of haemostasis and low-oestrogen oral contraceptives : what to expect?

Frequent requests from gynaecologists for testing of haemostatic parameters in women using hormonal contraception in order to predict development of thromboembolic disease, along with advancement of testing quality and accuracy, created the need to assess and compare the overall effect of oral contraceptives on today’s routine haemostatic tests. This 6-month prospective study included 195 women, first time users of oral contraceptives or with at least a 3-month pause before their entry in the study. Haemostatic changes were assessed by the following tests performed at three study time-points: at baseline, after three and after six months of taking oral contraceptives: prothrombin time, activated partial thromboplastin time, fibrinogen, resistance to activated protein C ratio, protein C activity, protein S activity, FVIII activity, antithrombin activity, plasminogen activity, α2-antiplasmin activity, inhibitor of plasminogen activator type 1 (PAI-1), and D-dimers. In addition, study subjects underwent genetic testing for FV Leiden mutation, FII G20210A mutation, and PAI-1 4G/5G polymorphism. Significant changes were found in all haemostatic variables except for FVIII activity. With in-depth analysis, we showed that PAI-1 concentration decreased only in subjects with PAI-1 4G/5G genotype. None of the subjects developed venous thromboembolic disease during the study. As most changes were within reference ranges, routine laboratory testing still does not appear to be recommendable in women without a known risk of thromboembolic disease.

oral contraceptives; blood coagulation; fibrinolysis

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

60 (5)

2014.

827-832

objavljeno

1433-6510

10.7754/Clin.Lab.2013.130533

Povezanost rada

Temeljne medicinske znanosti

Poveznice
Indeksiranost